Search Results - "McGlave, Philip B."

Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study by Bhatia, Smita, Francisco, Liton, Carter, Andrea, Sun, Can-Lan, Baker, K. Scott, Gurney, James G., McGlave, Philip B., Nademanee, Auayporn, O'Donnell, Margaret, Ramsay, Norma K.C., Robison, Leslie L., Snyder, David, Stein, Anthony, Forman, Stephen J., Weisdorf, Daniel J.

“…We assessed late mortality in 1479 individuals who had survived 2 or more years after allogeneic hematopoietic cell transplantation (HCT). Median age at HCT…”
Get full text

Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units by Verneris, Michael R., Brunstein, Claudio G., Barker, Juliet, MacMillan, Margaret L., DeFor, Todd, McKenna, David H., Burke, Michael J., Blazar, Bruce R., Miller, Jeffrey S., McGlave, Philip B., Weisdorf, Daniel J., Wagner, John E.

“…Umbilical cord blood (UCB) transplantation is potentially curative for acute leukemia. This analysis was performed to identify risk factors associated with…”
Get full text

Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study by Bhatia, Smita, Robison, Leslie L., Francisco, Liton, Carter, Andrea, Liu, Yan, Grant, Marcia, Baker, K. Scott, Fung, Henry, Gurney, James G., McGlave, Philip B., Nademanee, Auayporn, Ramsay, Norma K.C., Stein, Anthony, Weisdorf, Daniel J., Forman, Stephen J.

“…We assessed late mortality in 854 individuals who had survived 2 or more years after autologous hematopoietic cell transplantation (HCT) for hematologic…”
Get full text

Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia: Analysis of Graft Sources and Long-Term Outcome by TOMBLYN, Michael B, ARORA, Mukta, MACMILLAN, Margaret L, MCGLAVE, Philip B, MILLER, Jeffrey S, ORCHARD, Paul J, SLUNGAARD, Arne, TOMBLYN, Marcie R, VERCELLOTTI, Gregory M, VERNERIS, Michael R, WAGNER, John E, WEISDORF, Daniel J, BAKER, K. Scott, BLAZAR, Bruce R, BRUNSTEIN, Claudio G, BURNS, Linda J, DEFOR, Todd E, DUSENBERY, Kathryn E, KAUFMAN, Dan S, KERSEY, John H

“…Analysis of hematopoietic cell transplantation (HCT) for high-risk or recurrent acute lymphoblastic leukemia (ALL) using different donor sources is confounded…”
Get full text

Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics by Brunstein, Claudio G., Miller, Jeffrey S., Cao, Qing, McKenna, David H., Hippen, Keli L., Curtsinger, Julie, DeFor, Todd, Levine, Bruce L., June, Carl H., Rubinstein, Pablo, McGlave, Philip B., Blazar, Bruce R., Wagner, John E.

“…Acute graft-versus-host disease (aGVHD) is associated with high risk of morbidity and mortality and is a common complication after double umbilical cord blood…”
Get full text

Umbilical cord blood–derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect by Brunstein, Claudio G., Miller, Jeffrey S., McKenna, David H., Hippen, Keli L., DeFor, Todd E., Sumstad, Darin, Curtsinger, Julie, Verneris, Michael R., MacMillan, Margaret L., Levine, Bruce L., Riley, James L., June, Carl H., Le, Chap, Weisdorf, Daniel J., McGlave, Philip B., Blazar, Bruce R., Wagner, John E.

“…We studied the safety and clinical outcomes of patients treated with umbilical cord blood (UCB)-derived regulatory T cells (Tregs) that expanded in cultures…”
Get full text

Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease by Brunstein, Claudio G., Barker, Juliet N., Weisdorf, Daniel J., DeFor, Todd E., Miller, Jeffrey S., Blazar, Bruce R., McGlave, Philip B., Wagner, John E.

“…We evaluated the efficacy of umbilical cord blood (UCB) in the setting of a nonmyeloablative regimen consisting of fludarabine (200 mg/m2), cyclophosphamide…”
Get full text

Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy by Barker, Juliet N., Weisdorf, Daniel J., DeFor, Todd E., Blazar, Bruce R., McGlave, Philip B., Miller, Jeffrey S., Verfaillie, Catherine M., Wagner, John E.

“…Limited umbilical cord blood (UCB) cell dose compromises the outcome of adult UCB transplantation. Therefore, to augment graft cell dose, we evaluated the…”
Get full text

Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer by Miller, Jeffrey S., Soignier, Yvette, Panoskaltsis-Mortari, Angela, McNearney, Sarah A., Yun, Gong H., Fautsch, Susan K., McKenna, David, Le, Chap, Defor, Todd E., Burns, Linda J., Orchard, Paul J., Blazar, Bruce R., Wagner, John E., Slungaard, Arne, Weisdorf, Daniel J., Okazaki, Ian J., McGlave, Philip B.

“…We previously demonstrated that autologous natural killer (NK)–cell therapy after hematopoietic cell transplantation (HCT) is safe but does not provide an…”
Get full text

Impact of Allele-Level HLA Mismatch on Outcomes in Recipients of Double Umbilical Cord Blood Transplantation by Brunstein, Claudio G, Petersdorf, Effie W, DeFor, Todd E, Noreen, Harriet, Maurer, David, MacMillan, Margaret L, Ustun, Celalettin, Verneris, Michael R, Miller, Jeffrey S, Blazar, Bruce R, McGlave, Philip B, Weisdorf, Daniel J, Wagner, John E

“…Abstract The impact of allele-level HLA mismatch is uncertain in recipients of double umbilical cord blood (UCB) transplantation. We report a single-center…”
Get full text

Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report by Wu, Jessica, Chen, Yanjun, Hageman, Lindsey, Francisco, Liton, Ness, Emily C., Parman, Mariel, Kung, Michelle, Watson, James A., Weisdorf, Daniel J., Snyder, David S., McGlave, Philip B., Forman, Stephen J., Arora, Mukta, Armenian, Saro H., Bhatia, Ravi, Bhatia, Smita

“…Background Late mortality was investigated in patients with chronic myelogenous leukemia (CML) who underwent blood or bone marrow transplant (BMT) with or…”
Get full text

Long-Term Results of Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Hodgkin’s Lymphoma by Majhail, Navneet S., Weisdorf, Daniel J., Defor, Todd E., Miller, Jeffrey S., McGlave, Philip B., Slungaard, Arne, Arora, Mukta, Ramsay, Norma K.C., Orchard, Paul J., MacMillan, Margaret L., Burns, Linda J.

“…Autologous hematopoietic stem cell transplantation (ASCT) has become standard therapy for primary refractory (PR REF) or relapsed (REL) Hodgkin’s lymphoma…”
Get full text

Reduced-Intensity Allogeneic Transplant in Patients Older Than 55 Years: Unrelated Umbilical Cord Blood Is Safe and Effective for Patients without a Matched Related Donor by Majhail, Navneet S, Brunstein, Claudio G, Tomblyn, Marcie, Thomas, Avis J, Miller, Jeffrey S, Arora, Mukta, Kaufman, Dan S, Burns, Linda J, Slungaard, Arne, McGlave, Philip B, Wagner, John E, Weisdorf, Daniel J

“…Abstract The lower morbidity and mortality of reduced-intensity conditioning (RIC) regimens have allowed allogeneic hematopoietic cell transplantation (HCT) in…”
Get full text

Late effects in survivors of chronic myeloid leukemia treated with hematopoietic cell transplantation: results from the Bone Marrow Transplant Survivor Study by Baker, K. Scott, Gurney, James G., Ness, Kirsten K., Bhatia, Ravi, Forman, Stephen J., Francisco, Liton, McGlave, Philip B., Robison, Leslie L., Snyder, David S., Weisdorf, Daniel J., Bhatia, Smita

“…The purpose of this study was to analyze medical late effects among patients with chronic myeloid leukemia (CML) treated with hematopoietic cell…”
Get full text

Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience by McKenna Jr, David H., Sumstad, Darin, Bostrom, Nancy, Kadidlo, Diane M., Fautsch, Susan, McNearney, Sarah, DeWaard, Rose, McGlave, Philip B., Weisdorf, Daniel J., Wagner, John E., McCullough, Jeffrey, Miller, Jeffrey S.

“…BACKGROUND: Natural killer (NK) cells, a subset of lymphocytes and part of the innate immune system, play a crucial role in defense against cancer and viral…”
Get full text

Promising Progression-Free Survival for Patients Low and Intermediate Grade Lymphoid Malignancies after Nonmyeloablative Umbilical Cord Blood Transplantation by Brunstein, Claudio G, Cantero, Susana, Cao, Qing, Majhail, Navneet, McClune, Brian, Burns, Linda J, Tomblyn, Marcie, Miller, Jeffrey S, Blazar, Bruce R, McGlave, Philip B, Weisdorf, Daniel J, Wagner, John E

“…Abstract Nonmyeloablative hematopoietic cell transplantation (HCT) has been used to treat patients with advanced or high-risk lymphoid malignancies. We studied…”
Get full text

Adoptive Transfer of Umbilical Cord Blood-Derived Regulatory T Cells and Early Viral Reactivation by Brunstein, Claudio G, Blazar, Bruce R, Miller, Jeffrey S, Cao, Qing, Hippen, Keli L, McKenna, David H, Curtsinger, Julie, McGlave, Philip B, Wagner, John E

Get full text

A randomized study of the prevention of acute graft-versus-host disease by Ramsay, N K, Kersey, J H, Robison, L L, McGlave, P B, Woods, W G, Krivit, W, Kim, T H, Goldman, A I, Nesbit, Jr, M E

“…Acute graft-versus-host disease is a major problem in allogeneic bone-marrow transplantation. We performed a randomized study to compare the effectiveness of…”
Get more information

Autologous hematopoietic cell transplantation for chronic myelogenous leukemia by Bhatia, Ravi, McGlave, Philip B

“…Experimental and clinical evidence for persistence of polyclonal Philadelphia chromosome negative (Ph-) progenitors in chronic myelogenous leukemia (CML)…”
Get more information

The biology and treatment of chronic myelogenous leukemia by Brunstein, Claudio G, Mcglave, Philip B

“…Over the past 2 decades, our understanding of the pathobiological events underlying chronic myelogenous leukemia (CML) has grown. At the same time, effective…”
Get more information